Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Research & Development (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Research & Development for 7 consecutive years, with $348000.0 as the latest value for Q3 2025.

  • For Q3 2025, Research & Development rose 329.63% year-over-year to $348000.0; the TTM value through Sep 2025 reached $496000.0, up 95.28%, while the annual FY2024 figure was $286000.0, 81.12% down from the prior year.
  • Research & Development hit $348000.0 in Q3 2025 for Cyclerion Therapeutics, up from $56000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $12.1 million in Q2 2021 and bottomed at $24000.0 in Q4 2023.
  • Average Research & Development over 5 years is $3.3 million, with a median of $572000.0 recorded in 2023.
  • Year-over-year, Research & Development plummeted 97.96% in 2023 and then soared 329.63% in 2025.
  • Cyclerion Therapeutics' Research & Development stood at $10.5 million in 2021, then crashed by 88.76% to $1.2 million in 2022, then tumbled by 97.96% to $24000.0 in 2023, then surged by 133.33% to $56000.0 in 2024, then surged by 521.43% to $348000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $348000.0, $56000.0, and $36000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.